DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus®
KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing...
KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it...
Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®
Lexaria executing a triple-pronged strategy in obesity and diabetes
5th study arm in 12-week Phase 1b Study receives lead clinical site approval
Pursuing the world's first-ever orally-dosed liraglutide